View as Webpage

Camber Launches Generic Nymalize®

Piscataway, NJ, January 10, 2024 –Camber Pharmaceuticals is excited to announce the addition of Nimodipine Oral Solution.

Nimodipine Oral Solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition.

Nimodipine Oral Solution 60 mg/20 mL (3 mg/mL) is available and packaged in a 16-ounce bottle.

To find out more information on Nimodipine Oral Solution, please visit: www.camberpharma.com/nimodipine

Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.